ProQR Therapeutics NV (MEX:PRQRN) Beginning Cash Position: MXN1,630.1 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:PRQRN ProQR Therapeutics NV MEX:PRQRN
50 GF Score
Price MXN36.00
GF Value MXN39.89
! 2 Warning Signs
View Full Analysis

What is ProQR Therapeutics NV Beginning Cash Position?

ProQR Therapeutics NV MEX:PRQRN 50 Beginning Cash Position is MXN1,630.1 Mil as of Jun. 2026. GuruFocus rates MEX:PRQRN with a GF Score™ of 50/100 and a GF Value™ of MXN39.89. The stock has 2 warning signs investors should review.

ProQR Therapeutics NV's Beginning Cash Position for the quarter that ended in Jun. 2026 was MXN1,630.1 Mil.

ProQR Therapeutics NV's quarterly Beginning Cash Position declined from Dec. 2025 (MXN2,253.5 Mil) to Mar. 2026 (MXN1,926.5 Mil) and declined from Mar. 2026 (MXN1,926.5 Mil) to Jun. 2026 (MXN1,630.1 Mil).

ProQR Therapeutics NV's annual Beginning Cash Position increased from Dec. 2023 (MXN1,754.3 Mil) to Dec. 2024 (MXN2,597.1 Mil) and increased from Dec. 2024 (MXN2,597.1 Mil) to Dec. 2025 (MXN3,150.1 Mil).

ProQR Therapeutics NV Beginning Cash Position Related Terms

ProQR Therapeutics NV Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for ProQR Therapeutics NV's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProQR Therapeutics NV Beginning Cash Position Chart

ProQR Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,757.90 3,872.85 1,754.35 2,597.14 3,150.11

ProQR Therapeutics NV Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,875.72 2,578.63 2,253.52 1,926.54 1,630.07
MEX:PRQRN
50GF Score
ProQR Therapeutics NV MEX:PRQRN
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProQR Therapeutics NV Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of MXN1,630.1 Mil mean?
ProQR Therapeutics NV (MEX:PRQRN) has a Beginning Cash Position of MXN1,630.1 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on ProQR Therapeutics NV and its competitors.
Is ProQR Therapeutics NV's Beginning Cash Position too high?
ProQR Therapeutics NV's current Beginning Cash Position is MXN1,630.1 Mil. Overall, ProQR Therapeutics NV has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does ProQR Therapeutics NV's Beginning Cash Position compare to NWBO and IMRX?
ProQR Therapeutics NV's Beginning Cash Position of MXN1,630.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on ProQR Therapeutics NV and its competitors. ProQR Therapeutics NV's current Beginning Cash Position is MXN1,630.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProQR Therapeutics NV stock overvalued right now?
ProQR Therapeutics NV (MEX:PRQRN) has a current Beginning Cash Position of MXN1,630.1 Mil. The stock's GF Value™ is MXN39.89, compared to a current price of MXN36.00 — trading 9.8% below its estimated fair value. The current Beginning Cash Position is MXN1,630.1 Mil. ProQR Therapeutics NV's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For ProQR Therapeutics NV (MEX:PRQRN), the current Beginning Cash Position is MXN1,630.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ProQR Therapeutics NV (MEX:PRQRN) Overvalued in 2026?

Based on GuruFocus' analysis, ProQR Therapeutics NV stock appears to be undervalued. The current stock price of MXN36.00 is trading 9.8% below its estimated GF Value™ of MXN39.89.

Key valuation signals for MEX:PRQRN:

  • Beginning Cash Position: MXN1,630.1 Mil
  • GF Value™: MXN39.89 vs. price of MXN36.00 (9.8% below fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the MEX:PRQRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ProQR Therapeutics NV Business Description

Other Exchanges PRQR:USA0PQ:Germany
Address Zernikedreef 9, Leiden, ZH, NLD, 2333 CK
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
50GF Score

Get the complete analysis for MEX:PRQRN

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN36.00
Price
MXN39.89
GF Value